CALGB-40603

NCT00861705 📎

Regimen

Experimental
2x2 factorial: weekly paclitaxel +/- carboplatin (AUC 6 Q3W x 4) and +/- bevacizumab (10 mg/kg Q2W x 9), followed by dose-dense AC x 4.
Control
Weekly paclitaxel x 12 then dd-AC (no carboplatin, no bevacizumab).

Population

Stage II-III triple-negative breast cancer, treatment-naive, accrued in the US CALGB/Alliance network.

Key finding

CALGB-40603 first demonstrated carboplatin adds meaningful pCR benefit in TNBC neoadjuvant but without clear EFS/OS improvement at 5 years. Bevacizumab gave marginal pCR bump and no survival benefit.

Source: PMID 25092775

Timeline

  • Publication: 2015 Jan 1

Guideline citations

  • NCCN BREAST